NCT04839328View on ClinicalTrials.gov

A Phase Ⅲ Efficacy and Safety Study of Hemay005 in Subjects With Moderate to Severe Plaque Psoriasis

PHASE3CompletedINTERVENTIONAL
Enrollment

306

Participants

Timeline

Start Date

January 20, 2022

Primary Completion Date

October 25, 2022

Study Completion Date

July 28, 2023

Conditions
Psoriasis
Interventions
DRUG

60mg Hemay005

Hemay005 is a small molecule PDE4 inhibitor.

DRUG

Placebo

Placebos are the same as drugs, but contain no Hemay005.

Trial Locations (1)

100044

Peking University People's Hospital, Beijing

All Listed Sponsors
lead

Tianjin Hemay Pharmaceutical Co., Ltd

INDUSTRY